Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity
摘要:
Stereoselective syntheses of daedalin A and quercinol, an enantiomer of daedalin A, is described. The tyrosinase inhibitory activities of daedalin A and quercinol were examined. The activity of quercinol was weaker than that of daedalin A at high concentration. (C) 2009 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2009.12.034
作为产物:
描述:
daedalin A 在
palladium 10% on activated carbon 、 氢气 作用下,
以
乙醇 为溶剂,
反应 8.0h,
以100%的产率得到(2R)-6-hydroxy-2-hydroxymethyl-2-methyl-chroman
参考文献:
名称:
Daedalin A, a Metabolite ofDaedalea dickinsii, Inhibits Melanin Synthesis in anin VitroHuman Skin Model
The culture broth of Daedalea dickinsii was found to predominantly contain the tyrosinase inhibitor, (2R)-6-hydroxy-2-hydroxymethyl-2-methyl-2H-chromene, daedalin A (1). Ongoing research into bioactive metabolites resulted in the identification of two new 2H-chromenes, 6-hydroxy-5,7-dimethoxy-2,2-dimethyl-2H-chromene (3) and 6-hydroxy-2-hydroxymethyl-5-methoxy-2-methyl-2H-chromene (4), together with 6-hydroxy-2,2-dimethyl-2H-chromene (2). Comparative studies of isolated compounds 1–4 and related compounds (±)-1 and 1a–1c showed 1 to have the strongest tyrosinase inhibitory activity. These results suggest that the hydroxyl groups at positions 6 and 9 of 1 were important for the potent activity. A Lineweaver-Burk plot for a kinetic analysis indicates that 1 competed with l-tyrosine for tyrosinase. Compound 1 also suppressed melanogenesis in a human skin model (up to 49% at 2.8 μmol/tissue application) without affecting the cell viability. Compounds 1, 1b and 1c also showed 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity comparable to that of α-tocopherol.
Stereoselective syntheses of daedalin A and quercinol, an enantiomer of daedalin A, is described. The tyrosinase inhibitory activities of daedalin A and quercinol were examined. The activity of quercinol was weaker than that of daedalin A at high concentration. (C) 2009 Elsevier Ltd. All rights reserved.